health canada approval zepbound tirzepatide obesity canada 2024 2025 A 72-week trial compared the two leading GLP-1 medications in adults with (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the 📣 BIG NEWS IN OBESITY

In two population pharmacokinetic analyses of subjects with type 2 diabetes, mean liraglutide exposure was greater for female than male individuals after correction for differences in body weight [33, 35]

[13] Chemistry [edit] Structure [edit] Tirzepatide is an analog of the human GIP hormone with a C 20 fatty diacid portion attached, used to optimise the uptake and metabolism of the compound

The full range of BMIs in both groups ran from "healthy" to "severely obese ," with similar proportions of people in each category in each group

Although early trials of semaglutide and tirzepatide have shown promising results in improving symptoms, those findings were based on few clinical events, leaving treatment recommendations uncertain

Contraindications: If you are pregnant or nursing, consult your health care professional before taking this product.

Forecasting models often overestimate ROI: Many commercial forecasts fail to account for patient leakage, especially in obesity indications, leading to inflated expectations and missed market realities